版本:
中国

BRIEF-Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial

June 14 Aldeyra Therapeutics Inc

* Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial and plans for phase 3 clinical testing

* One-point reduction versus control component of primary endpoint not met

* Plans to initiate phase 3 clinical testing with 0.5% ADX-102 following discussion with regulatory authorities in second half of this year

* 0.5% ADX-102 statistically superior to control and demonstrates late-phase anti-inflammatory activity differentiated from standard of care

* Both concentrations of adx-102 were generally well tolerated and there were no safety concerns observed during trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐